Shamburg News · 8-K filed Oct 2, 2026, 4:30 PM EDT
Cingulate Extends Trial Period for Chief Medical Officer Matthew Brams' Employment
CING · Cingulate Inc.
- Leadership change
- Material agreement
- Materiality: medium
On September 30, 2026, Cingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc., entered into Amendment No. 2 to the employment agreement with Matthew N. Brams, Executive Vice President and Chief Medical Officer. The amendment extends the trial period for Mr. Brams' full-time employment from September 30, 2026 to December 31, 2026. The amendment is filed as Exhibit 10.1.
Source: SEC EDGAR, Form 8-K, Items 5.02, 9.01, accession 0001493152-26-045527.
Written from the filing by Shamburg Markets. Figures are as reported by the company.